Ferroptosis is an iron-dependent form of programmed cell death that is morphologically and biochemically distinct from apoptosis and other forms of cell death. Unlike apoptosis, which is characterized by shrinkage and fragmentation of cells, ferroptosis is characterized by the accumulation of lipid peroxides in the cell membrane, leading to cell membrane damage and subsequent cell death.
Ferroptosis was initially discovered as a response to oxidative stress but recent studies have implicated it in a range of diseases from cancer, neurodegeneration, and ischemia/reperfusion injury. Ferroptosis in cancer is thought to play a role in tumour suppression by eliminating cells with oncogenic mutations or those that are resistant to other forms of cell death.
To induce ferroptosis, several key pathways need to be targeted, including the glutathione peroxidase 4 (GPX4) pathway, the system xc- cystine/glutamate antiporter, and iron metabolism. Several compounds have been identified that can induce ferroptosis, including erastin, sulfasalazine, and sorafenib. However, many of these compounds have limited specificity and can induce off-target effects.
The development of specific inducers of ferroptosis is an active area of research, and several strategies are being pursued. These include the identification of small molecules that target specific components of the ferroptosis pathway, the development of nanoparticle-based delivery systems for ferroptosis inducers, and the use of CRISPR/Cas9 gene editing to identify novel regulators of ferroptosis.
The discovery of ferroptosis as a distinct form of cell death has opened up new avenues for the development of therapies for a range of diseases. Further research is needed to fully understand the mechanisms of ferroptosis and to develop safe and effective therapies that can be used in the clinic.